NASDAQ · ARTL
Artelo Biosciences, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ARTL: Nov 11, 2026
Artelo Biosciences, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-99.99.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews- RTTNews · Oct 7, 9:32 AM EDTArtelo Biosciences To Feature First Clinical Results For ART26.12 At BIO-Europe(RTTNews) – Artelo Biosciences (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced that it has been selected to deliver its first company presentation at BIO-Europe 2026 in Cologne, Germany.
- RTTNews · Sep 23, 10:38 AM EDTArtelo Expands ART27.13 Patent Coverage After Obesity Study Findings(RTTNews) – Artelo Biosciences, Inc. (ARTL) announced the filing of a provisional patent application covering the use of ART27.13 for the treatment of obesity, both as a standalone therapy and in combination with GLP-1 receptor agonists such as semaglutide, following recent noncl
- RTTNews · Sep 16, 8:57 AM EDTArtelo Reports ART27.13 Matches Semaglutide Weight Loss In Obesity Model(RTTNews) – Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company developing therapies targeting lipid-signaling pathways, announced new nonclinical data for ART27.13 showing weight loss comparable to semaglutide in an obesity model and greater weight loss when
- RTTNews · Aug 27, 9:49 AM EDTArtelo Biosciences Announces 1-for-9 Reverse Stock Split(RTTNews) – Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced Thursday a 1-for-9 reverse stock split of its common stock.
- RTTNews · Aug 20, 11:37 AM EDTArtelo Biosciences Secures Japanese Patent Allowance For ART27.13 Commercial Formulation(RTTNews) – Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company, announced on Thursday that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for patent claims covering the intended commercial formulation of ART27.13.
- RTTNews · Aug 18, 3:14 AM EDTArtelo Biosciences Receives U.S. Patent Notice Of Allowance For ART27.13; Stock Up(RTTNews) – Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company, said it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its application covering the intended commercial formulation of ART27.13 in development for cance
- RTTNews · Aug 10, 3:04 PM EDTArtelo Biosciences Enrolls First Patient In Phase 2 Glaucoma Study Of ART27.13(RTTNews) – Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced the enrollment of the first patient in the Phase 2 DREAM study evaluating ART27.13 in patients with glaucoma or ocular hypertension.
- RTTNews · Aug 10, 12:09 PM EDTArtelo Enrolls First Patient In Phase 2 DREAM Trial For ART27.13 In Treating Intralocular Pressure(RTTNews) – Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the enrollment of the first patient in the Phase 2 DREAM trial for ART27.13 in treating glaucoma or ocular hypertension.
- RTTNews · Jul 13, 11:00 AM EDTArtelo Biosciences Reports Positive ART27.13 Data In Neuropathy Model(RTTNews) – Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company announced encouraging results from nonclinical studies of ART27.13 in paclitaxel-induced peripheral neuropathy, a debilitating side effect of chemotherapy.
- RTTNews · Jul 13, 9:43 AM EDTArtelo Biosciences Announces Encouraging Data From Nonclinical Studies Of ART27.13, Stock Down(RTTNews) – Monday, Artelo Biosciences, Inc. (ARTL) announced results from nonclinical studies in neuropathic pain with ART27.13 for the treatment of patients experiencing cancer-related anorexia cachexia syndrome or CACS.
- RTTNews · Jun 10, 11:00 AM EDTArtelo Reports Positive Metabolite Data For Developing Analgesic ART26.12(RTTNews) – Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Wednesday released new metabolite analysis data for ART26.12, a developing analgesic.
- RTTNews · Apr 20, 9:51 AM EDTArtelo Reports Peer-reviewed Preclinical Evidence For FABP5 Inhibition In Pain Management; Stock Up(RTTNews) – Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the publication of a peer-reviewed article in the European Journal of Pain on the potential of FABP5 as a therapeutic target for pain management, and these results encourage a
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Artelo Biosciences, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.